Success examples
Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights

Müller M. R., Burmeister A., Skowron M. A., Stephan A., Bremmer F., Wakileh G. A., Petzsch P., Köhrer K., Albers P., Nettersheim D.

Clin Epigenetics 2022, 14 (1):5.

BET PROTAC
DOI
PubMed
General literature
Will the chemical probes please stand up?

Škuta C., Southan C., Bartůněk P.

RSC Med Chem. 2021, 12, 1428-1441.

DOI
PubMed
Success examples
Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket

Lloyd M. G., Huckvale R., Cheung K-M. J., Rodrigues M. J., Collie G. W., Pierrat O. A., Iou M. G., Carter M., Davis O. A., McAndrew P. C., Gunnell E., Le Bihan Y-V., Talbot R., Henley A. T., Johnson L. D., Hayes A., Bright M. D., Raynaud F. I., Meniconi M., Burke R., van Montfort R. L. M., Rossanese O. W., Bellenie B. R., Hoelder S.

J Med Chem. 2021, 64, 23, 17079-17097.

BCL6 inhibitor
DOI
PubMed
General literature
Chemical Probes for Understudied Kinases: Challenges and Opportunities

Serafim R. A. M., Elkins J. M., Zuercher W. J., Laufer S. A., Gehringer M.

J Med Chem. 2021, Online ahead of print.

DOI
PubMed
Success examples
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma

Pighi C., Cheong T.C., Compagno M., Patrucco E., Arigoni M., Olivero M., Wang Q., Lopez C., Bernhart S.H., Grande B.M., Poggio T., Langellotto F., Bonello L., Dall'Olio R., Martinez-Martin S., Molinaro L., Francia di Celle P., Whitfield J.R., Soucek L., Voena C., Calogero R.A., Morin R.D., Staudt L.M., Siebert R., Zamo A., Chiarle R.

Blood Adv 2021, 5(23):5239-5257.

BCL6 degrader BCL6 inhibitor BCL6 degrader
DOI
PubMed
General literature
Machine Learning Solicitation for COVID 19

Mohanty S. N., Saxena S. K., Satpathy S., Chatterjee J. M.

Springer 2021, ISBN 978-981-15-7316-3.